COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Xu Zhang, Ph.D.

Program Officer

Dr. Xu Zhang

Dr. Zhang is a Program Officer in the Office of Cancer Clinical Proteomics Research (OCCPR) at the National Cancer Institute (NCI), National Institutes of Health (NIH). She provides scientific expertise in Proteomics Data Science/Data Management, manages and oversees the grants and contracts that support proteomics data analysis, informatics and software tools, and data management activities for OCCPR’s CPTAC, International Cancer Proteogenome Consortium (ICPC), and the Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) network.

Prior to joining OCCPR, Dr. Zhang was a scientist within the Collaborative Protein Technology Resource at the NCI’s Center for Cancer Research (CCR). Dr. Zhang in this role, collaborated with CCR researchers to further investigate critical biological questions in their research through the use of mass spectrometry and proteomic data analysis. She has led and managed multiple intramural proteogenomic projects of studying tumor heterogeneity, identifying new targets for drug resistance, and developing MS-based quantitative assay for clinical cancer research of lung adenocarcinoma. Dr. Zhang has extensive experience in the proteogenomic field, especially in proteomics data management.

Dr. Zhang completed undergraduate training in Chemistry at Peking University, holds a MS degree in Inorganic Chemistry from Peking University, Ph.D. degree in Analytical Chemistry from the University of Wisconsin-Madison, and completed postdoctoral training in the Pacific Northwest National Laboratory (PNNL).